Aurdan Capital Management LLC Sells 3,178 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Aurdan Capital Management LLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,865 shares of the medical research company's stock after selling 3,178 shares during the quarter. Thermo Fisher Scientific accounts for 1.1% of Aurdan Capital Management LLC's portfolio, making the stock its 24th biggest holding. Aurdan Capital Management LLC's holdings in Thermo Fisher Scientific were worth $2,918,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Thermo Fisher Scientific in the fourth quarter worth $3,149,754,000. GAMMA Investing LLC boosted its stake in Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after purchasing an additional 1,433,444 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its stake in Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after purchasing an additional 858,193 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC boosted its stake in Thermo Fisher Scientific by 140.7% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock worth $569,062,000 after purchasing an additional 639,467 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 1.0%

Shares of Thermo Fisher Scientific stock traded up $4.29 on Friday, hitting $435.02. The company had a trading volume of 2,511,384 shares, compared to its average volume of 1,995,412. The stock has a market capitalization of $164.22 billion, a price-to-earnings ratio of 25.51, a P/E/G ratio of 2.29 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The stock has a 50 day moving average of $409.39 and a 200-day moving average of $476.59. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company posted $5.11 earnings per share. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. Barclays dropped their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 24th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Finally, The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $600.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.